Sai Life Expands Bidar API Capacity to 700 KL
ECONOMY & POLICY

Sai Life Expands Bidar API Capacity to 700 KL

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), a contract research, development, and manufacturing organisation (CRDMO) focused on pharmaceutical innovation, has announced the completion of Phase II of its new Production Block (PB-11) at its flagship API manufacturing facility in Bidar, Karnataka.
Phase I of PB-11, inaugurated in December 2024, added 110 kilolitres (KL) of capacity. With the addition of approximately 91 KL in Phase II during Q1 FY26, PB-11 now totals nearly 200 KL of reactor volume—making it the single largest production block at the site. This expansion increases Sai Life’s total installed reactor capacity at the Bidar facility to around 700 KL.

Commenting on the development, Krishna Kanumuri, CEO and Managing Director of Sai Life Sciences, stated, “This expansion is not just about capacity—it’s about scalability, reliability, and the ability to support clients as their needs evolve. We are enabling faster, more secure drug development by strengthening our commercial-scale API and intermediate manufacturing.”

PB-11 is a versatile block designed for the large-scale production of commercial products. Unit IV in Bidar serves as Sai Life’s core manufacturing hub, catering to highly regulated markets including the US, EU, and Japan.

Key features of the facility include:
  • 12 multipurpose production blocks totalling ~700 KL
  • Dedicated units for high-potency APIs (HPAPIs)
  • Advanced QC laboratories ensuring regulatory compliance
  • Capabilities such as lyophilisation, cryogenic and high-pressure reactions, and large-scale chromatography
The site has passed inspections by global regulatory bodies including the USFDA, Japan’s PMDA, and India’s CDSCO. As of March 2025, Sai Life’s manufacturing units had completed over 75 customer audits in the past three years—underscoring the company’s commitment to safety, quality, and regulatory excellence. 

Sai Life Sciences Limited (BSE: 544306 | NSE: SAILIFE), a contract research, development, and manufacturing organisation (CRDMO) focused on pharmaceutical innovation, has announced the completion of Phase II of its new Production Block (PB-11) at its flagship API manufacturing facility in Bidar, Karnataka.Phase I of PB-11, inaugurated in December 2024, added 110 kilolitres (KL) of capacity. With the addition of approximately 91 KL in Phase II during Q1 FY26, PB-11 now totals nearly 200 KL of reactor volume—making it the single largest production block at the site. This expansion increases Sai Life’s total installed reactor capacity at the Bidar facility to around 700 KL.Commenting on the development, Krishna Kanumuri, CEO and Managing Director of Sai Life Sciences, stated, “This expansion is not just about capacity—it’s about scalability, reliability, and the ability to support clients as their needs evolve. We are enabling faster, more secure drug development by strengthening our commercial-scale API and intermediate manufacturing.”PB-11 is a versatile block designed for the large-scale production of commercial products. Unit IV in Bidar serves as Sai Life’s core manufacturing hub, catering to highly regulated markets including the US, EU, and Japan.Key features of the facility include:12 multipurpose production blocks totalling ~700 KLDedicated units for high-potency APIs (HPAPIs)Advanced QC laboratories ensuring regulatory complianceCapabilities such as lyophilisation, cryogenic and high-pressure reactions, and large-scale chromatographyThe site has passed inspections by global regulatory bodies including the USFDA, Japan’s PMDA, and India’s CDSCO. As of March 2025, Sai Life’s manufacturing units had completed over 75 customer audits in the past three years—underscoring the company’s commitment to safety, quality, and regulatory excellence. 

Next Story
Building Material

Suraj Estate Wins Euromoney Award for India’s Best Residential Developer

"Suraj Estate Developers Limited has received the Euromoney Real Estate Award 2025 for ‘India’s Best Residential Developer’, positioning the company among globally benchmarked leaders in the sector. The recognition reflects its four-decade legacy in delivering high-quality residential and redevelopment-led projects across South Central Mumbai. The Euromoney Real Estate Awards, presented by the London-based Euromoney magazine, are widely regarded as one of the most credible global assessments of performance in real estate, banking and finance. Winners are selected through surveys of inte..

Next Story
Building Material

Lloyds Metals, Tata Steel Sign MoU to Explore Strategic Collaboration

"Lloyds Metals and Energy Limited has signed a non-binding Memorandum of Understanding with Tata Steel Limited to evaluate potential areas of strategic cooperation across mining, logistics, pelletisation and steelmaking. The MoU was signed by B Prabhakaran, Managing Director of Lloyds Metals, and Mr T V Narendran, CEO and Managing Director of Tata Steel. The partnership framework aims to leverage the natural operational synergies between both companies and assess opportunities in greenfield steel projects, iron ore mining, slurry pipeline infrastructure, pellet manufacturing in iron ore–ric..

Next Story
Building Material

IndiaAI, Gujarat Govt Host Regional Conclave Ahead of 2026 AI Summit

The IndiaAI Mission under the Ministry of Electronics and Information Technology, along with the Government of Gujarat and IIT Gandhinagar, convened a Regional Pre-Summit Event at Mahatma Mandir, Gandhinagar. The initiative is part of the build-up to the India–AI Impact Summit 2026, scheduled for 15–20 February 2026 at Bharat Mandapam, New Delhi. The conclave brought together senior policymakers, technology leaders, researchers and industry practitioners to examine how AI can accelerate economic, digital and social transformation across sectors. The programme focused on the overarching th..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Advertisement

Open In App